Sarah Demmon

Sarah is a Research Advisor in Bioproduct Research and Development at Eli Lilly and Company, where she has developed analytical control strategies for proteins, fusion proteins and monoclonal antibodies for over 20 years. She has developed, validated and transferred numerous methods globally through all stages of development during the span of her career. Sarah currently is a group leader in the analytical organization as well as oversees the technical agenda for a late stage asset. Sarah received her B.S. in analytical chemistry from Butler University and her M.S. in biochemistry from Purdue University prior to joining Eli Lilly.